ANTIRETROVIRAL DRUG LEVELS AND INTERACTIONS AFFECT LIPID, LIPOPROTEIN, AND

抗逆转录病毒药物水平和相互作用影响脂质、脂蛋白和

• 批准号: 7953989
• 负责人: Susan L. Rosenkranz
• 金额: $ 0.72万
• 依托单位: WASHINGTON UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2009
• 资助国家: 美国
• 起止时间: 2009-02-01 至 2010-01-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7953989
• 关键词: Adult; Affect; Amprenavir; Anti-Retroviral Agents; C-Peptide; Computer Retrieval of Information on Scientific Projects Database; Drug Kinetics; Enrollment; Fasting; Funding; Glucose; Grant; High Density Lipoprotein Cholesterol; Indinavir; Institution; Insulin; Lipids; Lipoprotein (a); Mass Spectrum Analysis; Measures; Metabolic; Metabolic syndrome; Methods; Modeling; Nelfinavir; Patients; Pharmaceutical Preparations; Protease Inhibitor; Randomized; Research; Research Personnel; Resources; Ritonavir; Saquinavir; Source; Triglycerides; United States National Institutes of Health; biomedical resource; efavirenz; glucose metabolism; non-nucleoside reverse transcriptase inhibitors; open label

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Background: HIV-infected patients treated with antiretroviral medications (ARVs) develop undesirable changes in lipid and glucose metabolism that mimic the metabolic syndrome and may be proatherogenic. Antiretroviral drug levels and their interactions may contribute to these metabolic alterations. Methods: Fifty six HIV-seronegative adults were enrolled in an open-label, randomized, pharmacokinetic interaction study, and received a nonnucleoside reverse transcriptase inhibitor (efavirenz on days 1-21) plus a protease inhibitor (PI; amprenavir on days 11-21), with a second PI on days 15-21 (saquinavir, nelfinavir, indinavir, or ritonavir). Fasting triglycerides, total LDL-and HDL-cholesterol, glucose, insulin, and C-peptide levels were measured on days 0, 14, 21, and 2-3 weeks after discontinuing drugs. Regression models were used to estimate changes in these parameters and associations between these changes and circulating levels of study drugs.

该副本是利用众多研究子项目之一 由NIH/NCRR资助的中心赠款提供的资源。子弹和 调查员（PI）可能已经从其他NIH来源获得了主要资金， 因此可以在其他清晰的条目中代表。列出的机构是 对于中心，这不一定是调查员的机构。 背景：接受抗逆转录病毒药物（ARV）治疗的HIV感染患者会在模仿代谢综合征的脂质和葡萄糖代谢中发生不良变化，并且可能具有促性疾病。抗逆转录病毒药物水平及其相互作用可能有助于这些代谢改变。方法：56名HIV副成年人参加了开放标签，随机，药代动力学相互作用研究，并接受了非核苷逆转录酶抑制剂（Efvavirenz在第1-21天）加上蛋白酶抑制剂（PI； PI; Amprenavir; Amprenavir in 11-21），第二天（Saef）（Saefir in Amecond piravir on 15-21） indinavir或Ritonavir）。在停用药物后的第0、14、21和2-3周测量了禁食甘油三酸酯，总LDL和HDL-胆固醇，葡萄糖，胰岛素和C肽水平。回归模型用于估计这些参数的变化以及这些变化与研究药物循环水平之间的关联。